ArticleMolecular biology reports2026
Mutational Spectrum of DMD Gene Variants and Cascade Screening Outcomes in the Central-Eastern Black Sea Region of Türkiye: A Single-Centre Retrospective Study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuchenne and Becker muscular dystrophies arise from pathogenic variants in the DMD gene at Xp21.2. Their spectrum is uncharacterised in the Central-Eastern Black Sea region of Türkiye.
methodsWe reviewed all consecutive individuals tested for DMD variants at our centre from January 2022 to February 2026. Multiplex ligation-dependent probe amplification was available in 45 of 47 and whole-gene sequencing in 16, run in parallel in 13. Variants were described against NM_004006.3 (LRG_199t1) and classified per the 2015 ACMG/AMP and 2020 ACMG/ClinGen copy-number standards.
resultsAmong 47 individuals (29 female, 18 male; median age 12.8 years, IQR 1.3-36.7), pathogenic variants were found in 19: ten probands and nine cascade-detected heterozygotes. Diagnostic yield in index testing was 30.3% (10/33; 95% CI 17.4-47.3%) and the cascade carrier-detection rate 64.3% (9/14; 95% CI 38.8-83.7%). Seven deletions and two sequence variants (NM_004006.3:c.701 C > G p.(Ser234Ter); c.2803 + 1G > T) were identified, six of nine families carrying distal-hotspot deletions (exons 45-55). Three deletions were in-frame and four out-of-frame, verified in LOVD and DOVE. Four heterozygotes, three of them probands, had unexplained hyperCKemia (776-2,816 U/L) without documented weakness; the one fully assessed had normal strength and echocardiogram. Two deletions were apparently de novo, and no proband was amenable to an approved exon-skipping oligonucleotide.
conclusionThe DMD variant spectrum in this first regional series was broadly congruent with national and global patterns, and cascade screening identified nine further heterozygotes. Given the small number of probands, these proportions are descriptive rather than prevalence estimates, and genotype-based phenotype assignment requires prospective confirmation.
Indexed as
Identifiers
42771065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.